NewLimit, a longevity biotechnology company co-founded by Coinbase CEO Brian Armstrong, has raised $435 million in a Series C funding round led by Founders Fund. New investors, including Thrive Capital, Greenoaks and Quiet Capital, joined existing backers such as Kleiner Perkins and Eli Lilly Ventures. The company develops age-reprogramming therapies designed to restore cell function affected by aging. The funding will support research and development as NewLimit prepares to move its first drug candidate into human clinical trials next year. The milestone marks a significant step toward testing its technology in patients.








